Patrick Mehlen News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials - News - PharmaTimes

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX as first-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma March 29th, 2023 LYON, France —NETRIS Pharma, a clinical-stage private biopharmaceutical company developin...

Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev - News - PharmaTimes

NETRIS Pharma, Orano and CLB have entered into a scientific collaboration agreement for the development of new antibody radio-conjugates to treat cancer.

 E-Mail A characteristic feature of all stem cells is their ability to self-renew. But how is this potential maintained throughout life? Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now discovered in mice that cells in the so-called "stem cell niche" are responsible for this: Blood vessel cells of the niche produce a factor that stimulates blood stem cells and thus maintains their self-ren...